ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Integrative Multi-Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- OLR1 drives gastric cancer progression through NF-κB activation and immunosuppressive macrophage polarization.Medical oncology (Northwood, London, England) · 2026Article
- A multi-omics integration of bulk and single-cell transcriptomics identifies and validates a 16-gene epithelial-mesenchymal transition prognostic signature in tongue squamous cell carcinoma.Translational cancer research · 2026Article
- Review
- Integrative Multi-Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Current understanding of immune characteristics in gastric cancer remains limited for guiding clinical practice, particularly immunotherapy. This study aims to elucidate the multidimensional landscape of tumor microenvironment in gastric cancer, identify predictive biomarkers potentially associated with favorable immunotherapy response, and propose a precision stratification framework to inform therapeutic strategies. This study introduces a novel immune classification system tumor immune microenvironment (TIME)-inflamed, TIME-desert, and TIME-excluded), and characterize the cellular and molecular characteristics of each subtype. TIME-inflamed tumors exhibit significantly higher infiltration of immune cells in tumor regions, as well as increased expression of inflamed-genes. TIME-desert tumors display minimal immune cell infiltration and feature abnormal microvasculature. TIME-excluded subtype is defined by immune cell accumulation outside the tumor with ineffective intratumoral infiltration, prominent fibroblast activity, and collagen deposition. Application of this immune classification system to stratify gastric cancer within the SPACE cohort successfully demonstrates potential for predicting favorable outcomes of a subset of "cold tumor" patients upon receiving combined immunotherapy and chemotherapy. The findings contribute to advancing the classification of gastric cancer from traditional histopathological subtyping to functional immunological subtyping, providing a valuable scientific foundation for precise patient stratification and the development of individualized immunotherapy strategies in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.